Call Scheduled for Today to Include General Corporate Update - HOUSTON, TX -- (http://www.financialnewsmedia.com News Alert) - Moleculin Biotech, Inc., (NASDAQ: MBRX) (\"Moleculin\" or the \"Company\"), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a reminder that it will host a conference call to discuss important positive developments regarding Annamycin, its drug candidate for the treatment of Acute Myeloid Leukemia, as well as to provide a general corporate update. (Read this and more details about Moleculin at http://financialnewsmedia.com/profiles/mbrx.html)



The call will be held today, October 20, 2016 at 5:00 pm Eastern Time and can be accessed with the following dial-in information:

Participant dial in (toll free): 1-877-418-3859 - Participant international dial in: 1-412-902-6506 - Please ask to be joined into the Moleculin call. - Participant Entry Number: 4494430



This conference call will be recorded and made available for replay as follows: US Toll Free: 1-877-344-7529 - International Toll: 1-412-317-0088 - Canada Toll Free:1-855-669-9658 - Replay Access Code: 10095171 - End Date: November 3, 2016



To access the replay using an international dial-in number, please select the link below: https://services.choruscall.com/ccforms/replay.html



About Moleculin Biotech, Inc. - Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient\'s own immune system. The other portfolio...